John Monahan

An experienced CEO-level executive of biotech companies focused on gene medicine and pharmaceutical companies with biotechnology research departments, John also currently sits on the boards of a number of private biotech companies.

In 1992, John founded Avigen, a biotech company that pioneered the development of gene medicines based on AAV vectors, which he spearheaded to become an industry standard. Over a 12-year period as CEO of Avigen, he took the company public, raised over $235 million, and led the company through a number of gene medicine Investigational New Drug applications.